Should You Buy This Stock That Makes "Viagra for Women"?
Last year, the U.S. Food and Drug Administration (FDA) approved Vyleesi, the second-ever treatment for premenopausal women who have low sexual desire (known as generalized hypoactive sexual desire disorder). Although investors' expectations were high, efforts by AMAG Pharmaceuticals (NASDAQ: AMAG) to commercialize the drug have gone haywire. A closer look into the drug's clinical data may reveal why.
Vyleesi is an agonist (a chemical that binds to receptors in the body) targeting melanocortin receptors in the central nervous system, which regulate sexual function. The drug is injected under the skin at least 45 minutes before sexual activities take place.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com
